LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 37

Search options

  1. Article ; Online: An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.

    Shrimp, Jonathan H / Kales, Stephen C / Sanderson, Philip E / Simeonov, Anton / Shen, Min / Hall, Matthew D

    ACS pharmacology & translational science

    2020  Volume 3, Issue 5, Page(s) 997–1007

    Abstract: SARS-CoV-2 is the viral pathogen causing the COVID19 global pandemic. Consequently, much research has gone into the development of preclinical assays for the discovery of new or repurposing of FDA-approved therapies. Preventing viral entry into a host ... ...

    Abstract SARS-CoV-2 is the viral pathogen causing the COVID19 global pandemic. Consequently, much research has gone into the development of preclinical assays for the discovery of new or repurposing of FDA-approved therapies. Preventing viral entry into a host cell would be an effective antiviral strategy. One mechanism for SARS-CoV-2 entry occurs when the spike protein on the surface of SARS-CoV-2 binds to an ACE2 receptor followed by cleavage at two cut sites ("priming") that causes a conformational change allowing for viral and host membrane fusion. TMPRSS2 has an extracellular protease domain capable of cleaving the spike protein to initiate membrane fusion. A validated inhibitor of TMPRSS2 protease activity would be a valuable tool for studying the impact TMPRSS2 has in viral entry and potentially be an effective antiviral therapeutic. To enable inhibitor discovery and profiling of FDA-approved therapeutics, we describe an assay for the biochemical screening of recombinant TMPRSS2 suitable for high throughput application. We demonstrate effectiveness to quantify inhibition down to subnanomolar concentrations by assessing the inhibition of camostat, nafamostat, and gabexate, clinically approved agents in Japan. Also, we profiled a camostat metabolite, FOY-251, and bromhexine hydrochloride, an FDA-approved mucolytic cough suppressant. The rank order potency for the compounds tested are nafamostat (IC
    Keywords covid19
    Language English
    Publishing date 2020-09-07
    Publishing country United States
    Document type Journal Article
    ISSN 2575-9108
    ISSN (online) 2575-9108
    DOI 10.1021/acsptsci.0c00106
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.

    Shrimp, Jonathan H / Kales, Stephen C / Sanderson, Philip E / Simeonov, Anton / Shen, Min / Hall, Matthew D

    bioRxiv : the preprint server for biology

    2020  

    Abstract: SARS-CoV-2 is the viral pathogen causing the COVID19 global pandemic. Consequently, much research has gone into the development of pre-clinical assays for the discovery of new or repurposing of FDA-approved therapies. Preventing viral entry into a host ... ...

    Abstract SARS-CoV-2 is the viral pathogen causing the COVID19 global pandemic. Consequently, much research has gone into the development of pre-clinical assays for the discovery of new or repurposing of FDA-approved therapies. Preventing viral entry into a host cell would be an effective antiviral strategy. One mechanism for SARS-CoV-2 entry occurs when the spike protein on the surface of SARS-CoV-2 binds to an ACE2 receptor followed by cleavage at two cut sites ("priming") that causes a conformational change allowing for viral and host membrane fusion. TMPRSS2 has an extracellular protease domain capable of cleaving the spike protein to initiate membrane fusion. A validated inhibitor of TMPRSS2 protease activity would be a valuable tool for studying the impact TMPRSS2 has in viral entry and potentially be an effective antiviral therapeutic. To enable inhibitor discovery and profiling of FDA-approved therapeutics, we describe an assay for the biochemical screening of recombinant TMPRSS2 suitable for high throughput application. We demonstrate effectiveness to quantify inhibition down to subnanomolar concentrations by assessing the inhibition of camostat, nafamostat and gabexate, clinically approved agents in Japan. Also, we profiled a camostat metabolite, FOY-251, and bromhexine hydrochloride, an FDA-approved mucolytic cough suppressant. The rank order potency for the compounds tested are: nafamostat (IC
    Keywords covid19
    Language English
    Publishing date 2020-08-06
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2020.06.23.167544
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Mitoribosome sensitivity to HSP70 inhibition uncovers metabolic liabilities of castration-resistant prostate cancer.

    Echtenkamp, Frank J / Ishida, Ryo / Rivera-Marquez, Genesis M / Maisiak, Marisa / Johnson, Oleta T / Shrimp, Jonathan H / Sinha, Arnav / Ralph, Stephen John / Nisbet, Ian / Cherukuri, Murali Krishna / Gestwicki, Jason E / Neckers, Leonard M

    PNAS nexus

    2023  Volume 2, Issue 4, Page(s) pgad115

    Abstract: The androgen receptor is a key regulator of prostate cancer and the principal target of current prostate cancer therapies collectively termed androgen deprivation therapies. Insensitivity to these drugs is a hallmark of progression to a terminal disease ... ...

    Abstract The androgen receptor is a key regulator of prostate cancer and the principal target of current prostate cancer therapies collectively termed androgen deprivation therapies. Insensitivity to these drugs is a hallmark of progression to a terminal disease state termed castration-resistant prostate cancer. Therefore, novel therapeutic options that slow progression of castration-resistant prostate cancer and combine effectively with existing agents are in urgent need. We show that JG-98, an allosteric inhibitor of HSP70, re-sensitizes castration-resistant prostate cancer to androgen deprivation drugs by targeting mitochondrial HSP70 (HSPA9) to suppress aerobic respiration. Rather than impacting androgen receptor stability as previously described, JG-98's primary effect is inhibition of mitochondrial translation, leading to disruption of electron transport chain activity. Although functionally distinct from HSPA9 inhibition, direct inhibition of the electron transport chain with a complex I or II inhibitor creates a similar physiological state capable of re-sensitizing castration-resistant prostate cancer to androgen deprivation therapies. These data identify a significant role for HspA9 in mitochondrial ribosome function and highlight an actionable metabolic vulnerability of castration-resistant prostate cancer.
    Language English
    Publishing date 2023-04-03
    Publishing country England
    Document type Journal Article
    ISSN 2752-6542
    ISSN (online) 2752-6542
    DOI 10.1093/pnasnexus/pgad115
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Nonspecific membrane bilayer perturbations by ivermectin underlie SARS-CoV-2

    Eastman, Richard T / Rusinova, Radda / Herold, Karl F / Huang, Xi-Ping / Dranchak, Patricia / Voss, Ty C / Rana, Sandeep / Shrimp, Jonathan H / White, Alex D / Hemmings, Hugh C / Roth, Bryan L / Inglese, James / Andersen, Olaf S / Dahlin, Jayme L

    bioRxiv : the preprint server for biology

    2023  

    Abstract: Since it was proposed as a potential host-directed antiviral agent for SARS-CoV-2, the antiparasitic drug ivermectin has been investigated thoroughly in clinical trials, which have provided insufficient support for its clinical efficacy. To examine the ... ...

    Abstract Since it was proposed as a potential host-directed antiviral agent for SARS-CoV-2, the antiparasitic drug ivermectin has been investigated thoroughly in clinical trials, which have provided insufficient support for its clinical efficacy. To examine the potential for ivermectin to be repurposed as an antiviral agent, we therefore undertook a series of preclinical studies. Consistent with early reports, ivermectin decreased SARS-CoV-2 viral burden in
    Language English
    Publishing date 2023-10-24
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.10.23.563088
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Methotrexate-based PROTACs as DHFR-specific chemical probes.

    Rana, Sandeep / Dranchak, Patricia / Dahlin, Jayme L / Lamy, Laurence / Li, Wenqing / Oliphant, Erin / Shrimp, Jonathan H / Rajacharya, Girish H / Tharakan, Ravi / Holland, David O / Whitten, Apryl S / Wilson, Kelli M / Singh, Pankaj K / Durum, Scott K / Tao, Dingyin / Rai, Ganesha / Inglese, James

    Cell chemical biology

    2023  Volume 31, Issue 2, Page(s) 221–233.e14

    Abstract: Methotrexate (MTX) is a tight-binding dihydrofolate reductase (DHFR) inhibitor, used as both an antineoplastic and immunosuppressant therapeutic. MTX, like folate undergoes folylpolyglutamate synthetase-mediated γ-glutamylation, which affects cellular ... ...

    Abstract Methotrexate (MTX) is a tight-binding dihydrofolate reductase (DHFR) inhibitor, used as both an antineoplastic and immunosuppressant therapeutic. MTX, like folate undergoes folylpolyglutamate synthetase-mediated γ-glutamylation, which affects cellular retention and target specificity. Mechanisms of MTX resistance in cancers include a decrease in MTX poly-γ-glutamylation and an upregulation of DHFR. Here, we report a series of potent MTX-based proteolysis targeting chimeras (PROTACs) to investigate DHFR degradation pharmacology and one-carbon biochemistry. These on-target, cell-active PROTACs show proteasome- and E3 ligase-dependent activity, and selective degradation of DHFR in multiple cancer cell lines. By comparison, treatment with MTX increases cellular DHFR protein expression. Importantly, these PROTACs produced distinct, less-lethal phenotypes compared to MTX. The chemical probe set described here should complement conventional DHFR inhibitors and serve as useful tools for studying one-carbon biochemistry and dissecting complex polypharmacology of MTX and related drugs. Such compounds may also serve as leads for potential autoimmune and antineoplastic therapeutics.
    MeSH term(s) Humans ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Carbon ; Folic Acid Antagonists/chemistry ; Folic Acid Antagonists/metabolism ; Folic Acid Antagonists/pharmacology ; Folic Acid Antagonists/therapeutic use ; Methotrexate/pharmacology ; Methotrexate/metabolism ; Methotrexate/therapeutic use ; Neoplasms/drug therapy ; Proteolysis Targeting Chimera ; Tetrahydrofolate Dehydrogenase/metabolism
    Chemical Substances Antineoplastic Agents ; Carbon (7440-44-0) ; Folic Acid Antagonists ; Methotrexate (YL5FZ2Y5U1) ; Proteolysis Targeting Chimera ; Tetrahydrofolate Dehydrogenase (EC 1.5.1.3)
    Language English
    Publishing date 2023-10-23
    Publishing country United States
    Document type Journal Article
    ISSN 2451-9448
    ISSN (online) 2451-9448
    DOI 10.1016/j.chembiol.2023.09.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19

    Shrimp, Jonathan H. / Kales, Stephen C. / Sanderson, Philip E. / Simeonov, Anton / Shen, Min / Hall, Matthew D.

    ACS Pharmacology & Translational Science

    2020  Volume 3, Issue 5, Page(s) 997–1007

    Keywords covid19
    Language English
    Publisher American Chemical Society (ACS)
    Publishing country us
    Document type Article ; Online
    ISSN 2575-9108
    DOI 10.1021/acsptsci.0c00106
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article: An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19

    Shrimp, Jonathan H. / Kales, Stephen C. / Sanderson, Philip E. / Simeonov, Anton / Shen, Min / Hall, Matthew D.

    ACS Pharmacology & Translational Science

    Abstract: SARS-CoV-2 is the viral pathogen causing the COVID19 global pandemic Consequently, much research has gone into the development of preclinical assays for the discovery of new or repurposing of FDA-approved therapies Preventing viral entry into a host cell ...

    Abstract SARS-CoV-2 is the viral pathogen causing the COVID19 global pandemic Consequently, much research has gone into the development of preclinical assays for the discovery of new or repurposing of FDA-approved therapies Preventing viral entry into a host cell would be an effective antiviral strategy One mechanism for SARS-CoV-2 entry occurs when the spike protein on the surface of SARS-CoV-2 binds to an ACE2 receptor followed by cleavage at two cut sites (“priming”) that causes a conformational change allowing for viral and host membrane fusion TMPRSS2 has an extracellular protease domain capable of cleaving the spike protein to initiate membrane fusion A validated inhibitor of TMPRSS2 protease activity would be a valuable tool for studying the impact TMPRSS2 has in viral entry and potentially be an effective antiviral therapeutic To enable inhibitor discovery and profiling of FDA-approved therapeutics, we describe an assay for the biochemical screening of recombinant TMPRSS2 suitable for high throughput application We demonstrate effectiveness to quantify inhibition down to subnanomolar concentrations by assessing the inhibition of camostat, nafamostat, and gabexate, clinically approved agents in Japan Also, we profiled a camostat metabolite, FOY-251, and bromhexine hydrochloride, an FDA-approved mucolytic cough suppressant The rank order potency for the compounds tested are nafamostat (IC50 = 0 27 nM), camostat (IC50 = 6 2 nM), FOY-251 (IC50 = 33 3 nM), and gabexate (IC50 = 130 nM) Bromhexine hydrochloride showed no inhibition of TMPRSS2 Further profiling of camostat, nafamostat, and gabexate against a panel of recombinant proteases provides insight into selectivity and potency
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #793483
    Database COVID19

    Kategorien

  8. Article ; Online: Probing the requirement for CD38 in retinoic acid-induced HL-60 cell differentiation with a small molecule dimerizer and genetic knockout.

    MacDonald, Robert J / Shrimp, Jonathan H / Jiang, Hong / Zhang, Lu / Lin, Hening / Yen, Andrew

    Scientific reports

    2017  Volume 7, Issue 1, Page(s) 17406

    Abstract: CD38 is an ectoenzyme and receptor with key physiological roles. It metabolizes ... ...

    Abstract CD38 is an ectoenzyme and receptor with key physiological roles. It metabolizes NAD
    MeSH term(s) ADP-ribosyl Cyclase 1/genetics ; ADP-ribosyl Cyclase 1/metabolism ; Antineoplastic Agents/pharmacology ; CD11b Antigen/metabolism ; CRISPR-Cas Systems ; Cell Differentiation/drug effects ; Cell Differentiation/physiology ; Gene Knockdown Techniques ; HL-60 Cells ; Humans ; Membrane Glycoproteins/genetics ; Membrane Glycoproteins/metabolism ; Protein Multimerization ; RNA, Messenger/metabolism ; Tretinoin/metabolism ; Tretinoin/pharmacology ; src-Family Kinases/metabolism
    Chemical Substances Antineoplastic Agents ; CD11b Antigen ; ITGAM protein, human ; Membrane Glycoproteins ; RNA, Messenger ; Tretinoin (5688UTC01R) ; src-Family Kinases (EC 2.7.10.2) ; CD38 protein, human (EC 3.2.2.5) ; ADP-ribosyl Cyclase 1 (EC 3.2.2.6)
    Language English
    Publishing date 2017-12-12
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-017-17720-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Discovery of TMPRSS2 inhibitors from virtual screening.

    Hu, Xin / Shrimp, Jonathan H / Guo, Hui / Xu, Miao / Chen, Catherine Z / Zhu, Wei / Zakharov, Alexey / Jain, Sankalp / Shinn, Paul / Simeonov, Anton / Hall, Matthew D / Shen, Min

    bioRxiv : the preprint server for biology

    2021  

    Abstract: The SARS-CoV-2 pandemic has prompted researchers to pivot their efforts to finding antiviral compounds and vaccines. In this study, we focused on the human host cell transmembrane protease serine 2 (TMPRSS2), which plays an important role in the viral ... ...

    Abstract The SARS-CoV-2 pandemic has prompted researchers to pivot their efforts to finding antiviral compounds and vaccines. In this study, we focused on the human host cell transmembrane protease serine 2 (TMPRSS2), which plays an important role in the viral life cycle by cleaving the spike protein to initiate membrane fusion. TMPRSS2 is an attractive target and has received attention for the development of drugs against SARS and MERS. Starting with comparative structural modeling and binding model analysis, we developed an efficient pharmacophore-based approach and applied a large-scale
    Language English
    Publishing date 2021-03-17
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2020.12.28.424413
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.

    Shrimp, Jonathan H / Janiszewski, John / Chen, Catherine Z / Xu, Miao / Wilson, Kelli M / Kales, Stephen C / Sanderson, Philip E / Shinn, Paul / Itkin, Zina / Guo, Hui / Shen, Min / Klumpp-Thomas, Carleen / Michael, Samuel G / Zheng, Wei / Simeonov, Anton / Hall, Matthew D

    bioRxiv : the preprint server for biology

    2022  

    Abstract: SARS-CoV-2 is the causative viral pathogen driving the COVID-19 pandemic that prompted an immediate global response to the development of vaccines and antiviral therapeutics. For antiviral therapeutics, drug repurposing allowed for rapid movement of ... ...

    Abstract SARS-CoV-2 is the causative viral pathogen driving the COVID-19 pandemic that prompted an immediate global response to the development of vaccines and antiviral therapeutics. For antiviral therapeutics, drug repurposing allowed for rapid movement of existing clinical candidates and therapies into human clinical trials to be tested as COVID-19 therapies. One effective antiviral treatment strategy used early in symptom onset is to prevent viral entry. SARS-CoV-2 enters ACE2-expressing cells when the receptor-binding domain of the spike protein on the surface of SARS-CoV-2 binds to ACE2 followed by cleavage at two cut sites on the spike protein. TMPRSS2 has a protease domain capable of cleaving the two cut sites; therefore, a molecule capable of inhibiting the protease activity of TMPRSS2 could be a valuable antiviral therapy. Initially, we used a fluorogenic high-throughput screening assay for the biochemical screening of 6030 compounds in NCATS annotated libraries. Then, we developed an orthogonal biochemical assay that uses mass spectrometry detection of product formation to ensure that hits from the primary screen are not assay artifacts from the fluorescent detection of product formation. Finally, we assessed the hits from the biochemical screening in a cell-based SARS-CoV-2 pseudotyped particle entry assay. Of the six molecules advanced for further studies, two are approved drugs in Japan (camostat and nafamostat), two have entered clinical trials (PCI-27483 and otamixaban), while the other two molecules are peptidomimetic inhibitors of TMPRSS2 taken from the literature that have not advanced into clinical trials (compounds 92 and 114). This work demonstrates a suite of assays for the discovery and development of new inhibitors of TMPRSS2.
    Language English
    Publishing date 2022-02-07
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2022.02.04.479134
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top